Ionizing radiation‑induced modification of nialamide as an anti‑inflammatory agent against lipopolysaccharide‑induced RAW 264.7 and DH82 cells
Experimental and Therapeutic Medicine · 11.03.2024 · 27 (5)
DOI: 10.3892/etm.2024.12480 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Therapeutic Medicine, online erschienen am 11.03.2024. Verfasst von Hanui Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Division for Biotechnology, Advanced Radiation Technology Institute (ARTI), Korea Atomic Energy Research Institute (KAERI), Jeongeup, Jeolla…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Nialamide is a non-selective monoamine oxidase inhibitor that was widely used as an antidepressant. However, it has been prohibited for decades in the depressive medicine market due to the adverse hepatotoxic side effects. The re-use of drugs that have been withdrawn from the market represents a promising approach for the development of novel incrementally modified drugs and, in this context, ionizing radiation can serve as a powerful tool for producing new drug candidates. The present study exposed nialamide to γ radiation at 50 kGy to obtain the novel cyclized benzylamide, nialaminosin (compound 2), along with five known compounds, 3-amino-N-benzylpropanamide (compound 3), 3-methoxy-N-benzylpropanamide (compound 4), 3-hydroxy-N-benzylpropanamide (HBPA; compound 5), N-benzylpropanamide (compound 6) and isonicotinamide (compound 7). Among the isolated compounds, HBPA was established to inhibit the lipopolysaccharide-induced overproduction of pro-inflammatory mediators, including nitric oxide (NO) and prostaglandin E2 and cytokines including TNF-α, IL-6 and IL-10, without causing cytotoxicity to both RAW 264.7 and DH82 cells. Furthermore, HBPA was found to reduce the protein expression of inducible NO synthase and cyclooxygenase-2 in macrophages and compared with nialamide, it was established to have more potent radical scavenging activity. The present study therefore suggested the application of HBPA for the improvement of anti-inflammatory properties using ionizing radiation technology on the withdrawn drug nialamide.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Division for Biotechnology, Advanced Radiation Technology Institute (ARTI), Korea Atomic Energy Research Institute (KAERI), Jeongeup, Jeollabuk 56212, Republic of Korea.
- Center for Companion Animal New Drug Development, Korea Institute of Toxicology (KIT), Jeongeup, Jeollabuk 56212, Republic of Korea.
- Medical Device Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI Hub), Daegu 41061, Republic of Korea.
- Department of Biology Education, Chonnam National University, Gwangju 61186, Republic of Korea.
- Radiation Biotechnology and Applied Radioisotope Science, University of Science and Technology (UST), Daejeon 34113, Republic of Korea.
Zitieren
APA
Lee, H., Jeong, G. H., Woo, S. Y., Choi, H. J., Chung, B. Y., Lee, K. B., & Bai, H. W. (2024). Ionizing radiation‑induced modification of nialamide as an anti‑inflammatory agent against lipopolysaccharide‑induced RAW 264.7 and DH82 cells. Experimental and Therapeutic Medicine, 27(5). https://doi.org/10.3892/etm.2024.12480
Vancouver
Lee H, Jeong GH, Woo SY, Choi HJ, Chung BY, Lee KB, et al. Ionizing radiation‑induced modification of nialamide as an anti‑inflammatory agent against lipopolysaccharide‑induced RAW 264.7 and DH82 cells. Experimental and Therapeutic Medicine. 2024;27(5). doi:10.3892/etm.2024.12480
BibTeX
@article{Lee2024,
author = {Lee, Hanui and Jeong, Gyeong Han and Woo, So-Yeun and Choi, Hyo Jin and Chung, Byung Yeoup and Lee, Kyung-Bon and Bai, Hyoung-Woo},
title = {Ionizing radiation‑induced modification of nialamide as an anti‑inflammatory agent against lipopolysaccharide‑induced RAW 264.7 and DH82 cells},
journal = {Experimental and Therapeutic Medicine},
year = {2024},
volume = {27},
number = {5},
doi = {10.3892/etm.2024.12480}
}
EUVIMED